Company Overview and News

to your dashboard

Headline News

Insiders Are Buying At 2 Attractive Biotechs

2018-01-19 seekingalpha
I have always found a strong correlation between insider buying and upside potential in the biotech sector. (121-1)

ROTY Edition 1 Volume 71: Thoughts On A Juno Buyout, Outperformance Continues And Other Updates

2018-01-19 seekingalpha
A buyout of Juno Therapeutics would likely provide a boost to the biotech sector if it actually occurs. (372-0)

ROTY Edition 1 Volume 67: Starting January On A Strong Note

2018-01-03 seekingalpha
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)

Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides Update

2017-12-31 seekingalpha
Today we will discuss the latest update from Progenics Pharmaceuticals (PGNX), which sparked a rally in pre-market trading on Friday. (162-1)

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

2017-12-31 seekingalpha
Today we will discuss an update from Intercept Pharmaceuticals (ICPT) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. (56-1)

ROTY Edition 1 Volume 64: Several Key Updates And Trades

2017-12-19 seekingalpha
While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018. (471-1)

Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering

2017-12-19 seekingalpha
Today we will focus on Ultragenyx Pharmaceutical (RARE). The company announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis (NVS) for $130 million. (215-1)

Biotech Forum Daily Digest: Spotlighting A Potential 'Razor & Razor Blade' Story

2017-12-19 seekingalpha
The biotech sector was a yo-yo last week as tax reform winded its way through Congress and due to lack of milestone events as we head into the holidays. (55-4)

Is It Time To Follow Insiders Into Reata Pharmaceuticals?

2017-12-19 seekingalpha
Results for bardoxolone methyl in treating chronic kidney disease caused by Alport syndrome were highly promising. (46-5)

Cormorant Asset Management, LLC - Current Holdings -

Cormorant Asset Management, LLC has disclosed 51 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 741,848,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Cormorant Asset Management, LLC's top holdings are MyoKardia, Inc. (NASDAQ:MYOK) , Ignyta, Inc. (NASDAQ:RXDX) , Omeros Corp. (NASDAQ:OMER) , AnaptysBio, Inc. (137-0)

Sphera Funds Management Ltd. - Current Holdings -

Sphera Funds Management Ltd. has disclosed 131 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 395,050,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Sphera Funds Management Ltd.'s top holdings are SPDR S&P Biotech ETF (NYSE:XBI) , Celgene Corp. (NASDAQ:CELG) , Biogen Inc. (NASDAQ:BIIB) , Merck & Co., Inc. (148-0)

RETA / Reata Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders -

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has 66 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13,892,503 shares. Largest shareholders include CPMG Inc, Rose William, Huff James Warren, Abbvie Inc., and Emerald Advisers Inc/pa. (72-0)

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

2017-10-23 reuters
* Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich’s Ataxia​ (5-0)

4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

2017-09-21 zacks
The biotech industry witnessed a rebound in 2017 despite facing some odds in the previous year. The industry faced some challenges like rising competition, pipeline setbacks, slowdown in growth of mature products and generic competition for certain key drugs in 2016. (131-2)

CUSIP: 75615P103